The estimated Net Worth of Dale L. Ludwig is at least 516 千$ dollars as of 19 November 2018. Dale Ludwig owns over 10,000 units of Actinium Pharmaceuticals Inc stock worth over 19,500$ and over the last 6 years he sold ATNM stock worth over 0$. In addition, he makes 496,614$ as Chief Scientific Officer at Actinium Pharmaceuticals Inc.
Sign up
Dale Ludwig ATNM stock SEC Form 4 insiders trading
Dale has made over 1 trades of the Actinium Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ATNM stock worth 4,500$ on 19 November 2018.
The largest trade he's ever made was buying 10,000 units of Actinium Pharmaceuticals Inc stock on 19 November 2018 worth over 4,500$. On average, Dale trades about 3,333 units every 0 days since 2018. As of 19 November 2018 he still owns at least 10,000 units of Actinium Pharmaceuticals Inc stock.
You can see the complete history of Dale Ludwig stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dale Ludwig biography
Dr. Dale L. Ludwig Ph.D. serves as Chief Scientific Officer of the Company. Dr. Ludwig has worked for 20 years in oncology antibody drug discovery and development at Eli Lilly and Company and at ImClone Systems, Inc., until its acquisition by Eli Lilly where he supported the development and successful launch of several biologic oncology drugs including Erbitux®, CyramzaTM, Portrazza®, and LartruvoTM as well as the clinical advancement of 10 additional therapeutic antibodies. Most recently, Dr. Ludwig served Chief Scientific Officer/Vice President of Oncology Discovery Research - Biologics Technology. in this role he was responsible for directing antibody discovery and development for oncology biologics and contributed to key strategic and project advancement efforts. Dr. Ludwig was a member of the Oncology Research Senior Leadership Team and directed the empowered antibody drug discovery programs that included collaborations with Immunogen and Zymeworks. Prior to the acquisition of Imclone by Eli Lilly and Company, Dr. Ludwig served as Head of Molecular & Cellular Engineering at IMClone Systems Incorporated. In this capacity, Dr. Ludwig served as core team leader for several ND filings and phase 1 advancements for novel antibodies. In addition, he directed and oversaw the full spectrum of drug development including antibody discovery, screening, selection, engineering, optimization, cloning and expression. Before his work in the biotechnology industry, Dr. Ludwig trained as a postdoctoral associate in the DNA Damage and Repair Group of the Los Alamos National Laboratory and as a postdoctoral fellow in the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati College of Medicine. Dr. Ludwig has a B.S. in biology with a concentration in microbiology from James Madison University and received his Ph.D. in Microbiology from East Carolina University.
What is the salary of Dale Ludwig?
As the Chief Scientific Officer of Actinium Pharmaceuticals Inc, the total compensation of Dale Ludwig at Actinium Pharmaceuticals Inc is 496,614$. There are 3 executives at Actinium Pharmaceuticals Inc getting paid more, with Sandesh Seth having the highest compensation of 1,102,720$.
How old is Dale Ludwig?
Dale Ludwig is 58, he's been the Chief Scientific Officer of Actinium Pharmaceuticals Inc since 2018. There are 5 older and 4 younger executives at Actinium Pharmaceuticals Inc. The oldest executive at Actinium Pharmaceuticals Inc is Ajit Shetty, 73, who is the Independent Director.
What's Dale Ludwig's mailing address?
Dale's mailing address filed with the SEC is C/O ACTINIUM PHARMACEUTICALS, INC., 275 MADISON AVENUE, 7TH FLOOR, NEW YORK, NY, 10016.
Insiders trading at Actinium Pharmaceuticals Inc
Over the last 7 years, insiders at Actinium Pharmaceuticals Inc have traded over 0$ worth of Actinium Pharmaceuticals Inc stock and bought 79,730 units worth 38,874$ . The most active insiders traders include Anil Kapur、Ajit Shetty、Sandesh Seth. On average, Actinium Pharmaceuticals Inc executives and independent directors trade stock every 41 days with the average trade being worth of 22,211$. The most recent stock trade was executed by Sandesh Seth on 10 December 2018, trading 10,000 units of ATNM stock currently worth 4,400$.
What does Actinium Pharmaceuticals Inc do?
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o
What does Actinium Pharmaceuticals Inc's logo look like?
Complete history of Dale Ludwig stock trades at Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc executives and stock owners
Actinium Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Sandesh Seth,
Chairman of the Board, Chief Executive Officer -
Sandesh C. Seth M.B.A., M.S., MBA,
Chairman & CEO -
Mark Berger,
Chief Medical Officer -
Dale Ludwig,
Chief Scientific Officer -
Steve O'Loughlin,
Principal Financial and Accounting Officer -
Steven O'Loughlin BS,
CFO & Corp. Sec. -
C. David Nicholson,
Lead Independent Director -
Richard Steinhart,
Independent Director -
Ajit Shetty,
Independent Director -
Jeffrey Chell,
Independent Director -
Dr. Bernie Cunningham P.M.P., Ph.D.,
Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management -
Dr. Arun Swaminathan Ph.D.,
Chief Bus. & Commercial Officer -
Dr. Avinash Desai M.D.,
Chief Medical Officer -
Dr. Mamata Gokhale,
VP & Global Head of Regulatory Affairs -
Dr. Robert N. Daly M.S., Ph.D.,
VP & Head of Clinical Operations -
Dr. Qing Liang,
VP & Head of Radiation Sciences -
Dr. Bernie Cunningham,
Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management -
Dr. David Gould,
Sr. VP of Corp. Devel. & Corp. Affairs -
Dr. Paul Diamond Esq., Ph.D.,
VP of Patent & Legal Counsel -
Nitya G. Ray,
Executive VP -
Anil Kapur,
Chief Commercial Officer